MarketBeat
07 Jun 2026, 10:04 UTC · 2h ago
CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies
MarketBeat
07 Jun 2026, 10:04 UTC · 2h ago
Story key points
5 claims · impact-rated
CareDx reported 39% year-over-year revenue growth in Q1 and updated its full-year revenue guidance to between $447 million and $465 million. — Strong top-line growth and updated guidance suggest accelerating momentum and improved commercial execution.
+0.60The acquisition of Naveris expands CareDx into the oncology MRD market, with expects of 30-40% year-over-year growth for the business over the next three years. — Diversification into a high-growth, reimbursed oncology segment provides a new long-term revenue stream beyond transplant diagnostics.
+0.50CareDx reported a Q1 adjusted EBITDA of $18.9 million and maintains a strong balance sheet with $189 million in cash and no debt. — Positive earnings and a clean balance sheet reduce financial risk and provide capital for further acquisitions or R&D.
+0.40Continue reading
6 related stories
Top 3 movers · tap to explore
The company's top pipeline priority, AlloHeme, is not expected to see meaningful commercial effort until early 2027 with coverage potentially arriving in 2028. — The long lead time for the primary pipeline priority limits the near-term growth catalyst potential of the R&D engine.
-0.20Lab Products revenue declined 4% in the first quarter, which management attributed to timing of stocking orders. — A decline in a business segment is generally negative, though management's explanation suggests it is a temporary timing issue rather than a structural decline.
-0.10Ticker attribution
Model heads
Reported 39% year-over-year revenue growth, strong first-quarter performance, and a clear growth strategy including a strategic acquisition.
Mentioned as a partner in long-term agreements that contribute to CareDx's stable margin profile.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
7 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
The Motley Fool
1h ago
